The London Technology and Life Sciences team advised LabGenius on the completion of its $15 million Series A extension round bringing the round total to $25 million. The financing round was led by Atomico with participation from Lux Ventures, Obvious Ventures, Kindred Capital and individual investors.
LabGenius is a protein engineering company that combines artificial intelligence, robotic automation and synthetic biology to evolve next-generation protein therapeutics. The UK company’s platform, EVA, is designed to rapidly identify and test potential new drugs, which cuts down the cost and risk associated with drug development. By combining robotic automation, synthetic biology and machine learning, the team can systematically search through billions of protein designs and test those that are predicted to be high performing.For more details on the financing, please read the press release.